Global Next Generation Diabetes Therapy and Drug Delivery Market was valued at $617 million in 2015 and is expected to garner $9,673 million by 2022, registering a CAGR of 41.1% during the forecast period 2016 2023. The next generation diabetes therapy and the drug delivery devices are the advanced form of diabetic products that improve the quality of life of diabetic patients. Oral and inhalable insulin introduce a different mode of insulin delivery in diabetic patients, and are a painless mode of introducing insulin than the injectable insulins, reducing the risk of skin irritation caused due to needles. In addition, the dose volume is easily calculated in oral & inhalable insulin and helps to maintain the dosage time. Advanced diabetic therapy in the form of insulin patches, continuous glucose monitoring systems (CGMS), and artificial pancreas helps to improves management of blood sugar level and reduces the risk of any diabetic-related complications.
Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/2098
Next generation diabetes therapy and drug delivery devices are used to check the blood glucose levels and deliver insulin into the body. Next generation diabetes drug delivery systems, such as oral and inhalable insulin, help introduce insulin into the patients body without causing pain and reduce the risk of skin irritation, owing to frequent use of needles. Advancements in diabetes therapy systems, such as insulin patch, continuous glucose monitoring (CGM) system, and artificial pancreas, are frequently used to detect the glucose levels and adjust the insulin levels to manage the change in glucose levels.
Rise in the number of diabetics and the benefits of using advanced diabetic devices, such as artificial pancreas and insulin patches over conventional products, are expected to boost the growth of next generation diabetes therapy and drug delivery market. Furthermore, the increase in disposable income among the diabetic patients and technological advancement of next generation diabetic products areanticipated to fuel the market growth. The rise in healthcare expenditure in the developing countries, such as India and China, is expected to provide opportunities for market expansion. However, lack of awareness, less variability in products, and cost restrains in the developing regions are expected to hamper the market growth.
CGM system is a well-established product and dominates the market, attributed to the presence of a large patient base suffering from diabetes with highest share in 2015, and is anticipated to continue this trend in the future, in terms of revenue. Advantages of these systems as compared to conventional diabetic products are ease of usage and efficient & early detection of change in blood glucose levels, which are expected to boost the growth of this segment.
Get More Information Report @ https://www.alliedmarketresearch.com/purchase-enquiry/2098
Diagnostics/clinics was the highest contributor and is anticipated to continue its dominance during the analysis period, and has accounted for about half of the share of the global market in 2015, due to the increase in procurement of the products from diagnostics and clinics by diabetic patients.
In 2015, North America displayed maximum contribution to the total revenue generated, while Asia-Pacific is expected to witness the highest CAGR of 50.2%, due to rise in disposable income, improvement in healthcare expenditure, and increase in adoption rate of advanced diabetic products.
The key companies profiled in the report include
• Abbott Laboratories,• Medtronic, Inc., • Sanofi, • Novo Nordisk, • MannKind Corporation, • Enteris BioPharma, • Dexcom, Inc., • Senseonics Holding, Inc., • Medtech, and • Johnson & Johnson.
Table Of Content
Chapter: 1 INTRODUCTION1.1. REPORT DESCRIPTION1.2. KEY BENEFITS1.3. KEY MARKET SEGMENTS1.4. RESEARCH METHODOLOGY1.4.1. Secondary research1.4.2. Primary research1.4.3. Analyst tools and models
Chapter: 2 EXECUTIVE SUMMARY2.1. CXO PERSPECTIVE
Chapter: 3 MARKET OVERVIEW3.1. KEY BENEFITS3.1.1. Top investment pockets3.1.2. Top winning strategies3.2. PATENT ANALYSIS3.2.1. Patent analysis by year3.2.2. Patent analysis by region3.2.3. Patent analysis by product3.3. GOVERNMENT REGULATIONS3.3.1. U.S. FDA3.3.2. Europe CE Mark3.3.3. Ministry of Health, Labour, and Welfare (MHLW)3.4. REIMBURSEMENT POLICIES3.5. INNOVATIONS IN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET3.5.1. Smart contact lenses for glucose monitoring3.5.2. iLet bihormonal bionic pancreas3.5.3. Glucose nanosensors3.5.4. Beta cell replacement therapy3.5.5. Glucose-responsive insulin-producing cells3.6. MARKET DYNAMICS3.6.1. Drivers3.6.1.1. Rise in incidence of diabetes3.6.1.2. Rise in healthcare expenditure & disposable income3.6.1.3. Benefits of using next generation diabetes products over conventional products3.6.2. Restraints3.6.2.1. Cost restrains3.6.2.2. Lack of awareness3.6.2.3. Less variability in products3.6.3. Opportunities3.6.3.1. Developing products with fewer side effects at affordable costs3.6.3.2. High undiagnosed diabetic patient population3.6.3.3. Tapping potential in developing regions…
Media ContactCompany Name: Allied Market ResearchContact Person: David CorreaEmail: Send EmailPhone: +1-800-792-5285Address:5933 NE Win Sivers Drive #205City: PortlandState: OR 97220Country: United StatesWebsite: www.alliedmarketresearch.com/press-release/next-generation-diabetes-therapy-and-drug-delivery-market.html